BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 1, 2025
See today's BioWorld MedTech
Home
» Davita to pay $34.5 million to settle allegations of violation of AKS
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Davita to pay $34.5 million to settle allegations of violation of AKS
July 22, 2024
By
Mark McCarty
Denver-based Davita Inc. agreed to pay more than $34 million to settle allegations that the company violated the Anti-Kickback Statute (AKS) by not collecting management fees from physicians to induce referrals to the company’s dialysis clinics.
BioWorld MedTech
U.S.